http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Norihiro Furusyo ),( Ahmed H. Walaa ),( Kunimitsu Eiraku ),( Kazuhiro Toyoda ),( Eiichi Ogawa ),( Hiroaki Ikezaki ),( Takeshi Ihara ),( Takeo Hayashi ),( Mosaburo Kainuma ),( Masayuki Murata ),( Jun 대한간학회 2011 Gut and Liver Vol.5 No.4
Background/Aims: Helicobacter pylori infection causes gastritis, peptic ulcers and gastric malignancies, and its eradication has been advocated by many groups. We determined the H. pylori carrier status and eradication rates of patients with chronic hepatitis C virus (HCV) infection. Methods: In total, 76 chronically HCV-infected patients were enrolled for comparison with 228 HCV-noninfected, age- and sex-matched controls. H. pylori infection was confirmed by H. pylori antibody and urea breath testing. Results: The H. pylori infection rate was significantly higher for HCV-infected patients (67 of 76, 88.2%) than for HCV-noninfected controls (158 of 228, 69.3%). Endoscopic fi ndings showed that the rates of gastric ulcers and gastritis were significantly higher for the 67 HCV-infected patients with H. pylori infection (34.3% and 77.6%) than for the 158 HCV-noninfected controls with H. pylori infection (15.2% and 57.6%). Treatment to eradicate H. pylori had a signifi cantly higher success rate for HCV-infected patients (61 of 67, 91.0%) than for HCV-noninfected controls (115 of 158, 72.8%). Conclusions: The markedly high H. pylori eradication rate observed in this study shows that eradication of H. pylori holds promise for the improvement of the long-term health condition of patients with chronic HCV infection. (Gut Liver 2011;5:447-453)
T. Ogawa,K. Seto,D. Hasegawa,H. T. Yang,H. Kura,M. Doi,M. Takahashi 한국자기학회 2011 Journal of Magnetics Vol.16 No.3
In order to obtain mono-dispersed Fe NPs with high saturation magnetization, quantitative analysis method to investigate the growth dynamics of the Fe NPs synthesized by a conventional thermal decomposition method has been developed. As a result, fast nucleation process promotes formation of ~4 ㎚ of initial nucleus with a non-equilibrium phase, resulting in low saturation magnetization. And slow particle growth with atomic-scaled surface precipitation mode (< 100 atoms/(minㆍ㎚²)) can form the growth layer on the surface of initial nucleus with high saturation magnetization (~190 emu/gFe) as an equilibrium a phase of Fe. Therefore, higher stabilization of small initial nucleus generated just after the injection of Fe(CO)? should be one of the key issues to achieve much higher Ms of Fe NPs.
Watanabe, H.,Lorusso, G.,Nishimura, S.,Otsuka, T.,Ogawa, K.,Xu, Z. Y.,Sumikama, T.,Sö,derströ,m, P.-A.,Doornenbal, P.,Li, Z.,Browne, F.,Gey, G.,Jung, H. S.,Taprogge, J.,Vajta, Zs.,Wu, J.,Yagi, American Physical Society 2014 Physical Review Letters Vol.113 No.4
<P>A new isomer with a half-life of 23.0(8) ms has been identified at 2406 keV in (126)Pd and is proposed to have a spin and parity of 10(+) with a maximally aligned configuration comprising two neutron holes in the 1h(11/2) orbit. In addition to an internal-decay branch through a hindered electric octupole transition, β decay from the long-lived isomer was observed to populate excited states at high spins in (126)Ag. The smaller energy difference between the 10(+) and 7(-) isomers in (126)Pd than in the heavier N=80 isotones can be interpreted as being ascribed to the monopole shift of the 1h(11/2) neutron orbit. The effects of the monopole interaction on the evolution of single-neutron energies below (132)Sn are discussed in terms of the central and tensor forces.</P>
XMASS Collaboration,Takiya, H.,Abe, K.,Hiraide, K.,Ichimura, K.,Kishimoto, Y.,Kobayashi, K.,Kobayashi, M.,Moriyama, S.,Nakahata, M.,Norita, T.,Ogawa, H.,Sekiya, H.,Takachio, O.,Takeda, A.,Tasaka, S.,Y North-Holland 2016 Nuclear Instruments & Methods in Physics Research. Vol.834 No.-
We report the measurement of the emission time profile of scintillation from gamma-ray induced events in the XMASS-I 832kg liquid xenon scintillation detector. Decay time constant was derived from a comparison of scintillation photon timing distributions between the observed data and simulated samples in order to take into account optical processes such as absorption and scattering in liquid xenon. Calibration data of radioactive sources, <SUP>55</SUP>Fe, <SUP>241</SUP>Am, and <SUP>57</SUP>Co were used to obtain the decay time constant. Assuming two decay components, τ<SUB>1</SUB> and τ<SUB>2</SUB>, the decay time constant τ<SUB>2</SUB> increased from 27.9ns to 37.0ns as the gamma-ray energy increased from 5.9keV to 122keV. The accuracy of the measurement was better than 1.5ns at all energy levels. A fast decay component with τ<SUB>1</SUB>~2ns was necessary to reproduce data. Energy dependencies of τ<SUB>2</SUB> and the fraction of the fast decay component were studied as a function of the kinetic energy of electrons induced by gamma-rays. The obtained data almost reproduced previously reported results and extended them to the lower energy region relevant to direct dark matter searches.
Kim, T,Yoshida, K,Kim, Y K,Tyndel, M S,Park, H J,Choi, S H,Ahn, J-S,Jung, S-H,Yang, D-H,Lee, J-J,Kim, H J,Kong, G,Ogawa, S,Zhang, Z,Kim, H J,Kim, D D Macmillan Publishers Limited 2016 Leukemia Vol.30 No.2
<P>Most types of cancers are made up of heterogeneous mixtures of genetically distinct subclones. In particular, acute myeloid leukemia (AML) has been shown to undergo substantial clonal evolution over the course of the disease. AML tends to harbor fewer mutations than solid tumors, making it challenging to infer clonal structure. Here, we present a 9-year, whole-exome sequencing study of a single case at 12 time points, from the initial diagnosis until a fourth relapse, including 6 remission samples in between. To the best of our knowledge, it covers the longest time span of any data set of its kind. We used these time series data to track the hierarchy and order of variant acquisition, and subsequently analyzed the evolution of somatic variants to infer clonal structure. From this, we postulate the development and extinction of subclones, as well as their anticorrelated expansion via varying drug responses. In particular, we show that new subclones started appearing after the first complete remission. The presence and absence of different subclones during remission and relapses implies differing drug responses among subclones. Our study shows that time series analysis contrasting remission and relapse periods provides a much more comprehensive view of clonal structure and evolution.</P>
( Mindie H. Nguyen ),( Norihiro Furusyo ),( Dae Won Jun ),( Ming-Lung Yu ),( Jia-Horng Kao ),( Masaru Enomoto ),( Eiichi Ogawa ),( Etsuko Ilio ),( Chen-Hua Liu ),( Akihiro Tamori ),( Chia-Yen Dai ),( 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Since their recent introduction in Asia, IFN-free DAAs have revolutionized treatment of chronic hepatitis C across all HCV genotypes. However, experience from large and diverse routine clinical practice is still limited. The aim of this study was to report real-world outcomes from a large multinational co hort of East Asian HCV patients treated with IFN-free DAAs. Methods: Data were obtained using a required case report form from the REAL-C registry of patients who were initiated on IFN-free DAA therapy in routine practice and represented 10 study centers inclusive of 30 clinical sites in Hong Kong, Japan, Korea, and Taiwan. Cirrhosis was determined by liver biopsy, noninvasive tests (elastography/fibroscan, fibrotest), or the presence of clinical, radiologic, endoscopic, laboratory evidence of cirrhosis and/or portal hypertension. Results: A total of 3702 patients have been registered. Table 1 displays the patient characteristics. The average age was 63.6±12.8; 17.7% had diabetes, 8.7% had chronic renal impairment, 26% had cirrhosis (5.1% decompensated cirrhosis), and 5.4% had HCC at baseline or prior to DAA treatment initiation. The majority of patients were HCV GT1 (68.7%), followed by HCV GT2 (30.4%). Ten different DAA regimens were used, with the majority receiving LDV/SOF (43.7%), followed by SOF+RBV (27.8%). One-third were treatment experienced (24.8% with prior PEG-IFN+RBV, 4.5% with prior DAA). SVR12 overall rate was 96.6%. Significant decreases noted in all major liver enzymes at week 12 and 24 post treatment. No increase in creatinine noted across treatments; 3.2% stopped treatment and 13.4% had an adverse event with fatigue (5.6% in patients treated with RBV vs. 6.4% in those treated without RBV, P=0.61) and anemia (5.6%) the most reported. Table 2 displays SVR12 rates by cirrhosis and prior treatment status for the most commonly used DAA treatments for GT1 and GT2 patients. SVR12 rates were excellent ranging from 97.1% (95%CI: 94.1-98.8%) to 99.7% (95%CI: 99.0-99.9%) for GT1 patients treated with LDV/SOF who did not have cirrhosis regardless of prior treatment history and who were treatment-naive with cirrhosis but lower in the cirrhotic treatment-experienced group (92.2%; 95%CI: 86.7-95.9%) (P<0.0001). Sub-analysis results for GT1b were similar, with SVR12 99.7% for non-cirrhotic treatment-naive, 99.5% for non-cirrhotic treatment-experienced, 97.4% for cirrhotic treatment-naive, and 93.0% for cirrhotic treatment-experienced, (P<0.0001). For GT2 patients, SVR12 was excellent for all groups (96.8-98.0%) except for cirrhotic treatment-experienced patients (n=66) who experienced an SVR12 of 87.9% (95%CI: 77.5-94.6%) (P=0.002). Conclusions: HCV cure rates were high overall in the REALC cohort-LDV/SOF GT1 98%; SOF+RBV GT2 96% except for cirrhotic, treatment-experienced patients especially in GT2, suggesting alternative therapy is needed.